SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sandu Pharmaceuticals informs about closure of trading window

21 Mar 2022 Evaluate

Pursuant to the ‘Code of Conduct for Prevention of Insider Trading’ of the Company, SEBI (Prohibition of Insider Trading)Regulations, 2015 and clarification given by BSE vide its letter ref no LIST/COMP/01/2019-20 dated April 2,2019 regarding trading restrictions period, Sandu Pharmaceuticals has informed that the trading window for dealing in Securities of the Company shall remain closed from Friday, 01st April 2022 till 48 hours after the declaration of the financial results of the Company for the Quarter ended 31st March 2022 for Directors, KMPs, Promoters And Promoters Group and Designated Persons etc covered under the Code.

The above information is a part of company’s filings submitted to BSE.

Sandu Pharmaceutical Share Price

43.80 0.16 (0.37%)
24-Apr-2026 15:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1622.40
Dr. Reddys Lab 1317.10
Cipla 1293.35
Zydus Lifesciences 927.90
Lupin 2295.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×